Berenice Reed-Gitomer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Berenice Reed-Gitomer has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Kim McFann
Division of Renal Diseases and Hypertension, Department of Medicine, School of Medicine, University of Colorado Denver, Aurora, Colorado, USA
2 shared publicationsRobert W. Schrier
Division of Renal Diseases and Hypertension, Department of Medicine, School of Medicine, University of Colorado Denver, Aurora, Colorado, USA
2 shared publications- Alexander T Pennington
Department of Anesthesiology, University of Colorado, Aurora, CO, USA
1 shared publication - Amirali Masoumi
Department of Medicine, Division of Cardiology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY
1 shared publication - Charles L. Edelstein
Division of Renal Diseases and Hypertension, University of Colorado at Denver, Aurora, Colorado
1 shared publication David M. Maahs
University of Colorado Denver, School of Medicine, Department of Pediatrics, Aurora, Colorado
1 shared publication
Latest Publications
- 1 October 2013
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 305 (7) , F975-F976
Vitamin D deficiency: a nontraditional risk factor in polycystic kidney disease?
- 1 October 2013
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 305 (7) , F975-F976
Vitamin D deficiency: a nontraditional risk factor in polycystic kidney disease?
- Open Access
- 31 July 2013
- Published by Springer Nature in BMC Nephrology
- Vol. 14 (1) , 165
Effects of lovastatin treatment on the metabolic distributions in the Han:SPRD rat model of polycystic kidney disease
We previously demonstrated that lovastatin decreases cyst volume and improves kidney function in the Han:SPRD (Cy/+) rat model of ADPKD. Since endothelial dysfunction and inflammatory activity are evident in patients with ADPKD, we investigated whether lovastatin reduces the inflammation and vascular dysfunction and improves kidney cell energy metabolism of Cy/+ rats.
- 31 July 2013
- Published by Springer Nature in BMC Nephrology
- Vol. 14 (1) , 165
Open AccessEffects of lovastatin treatment on the metabolic distributions in the Han:SPRD rat model of polycystic kidney disease
We previously demonstrated that lovastatin decreases cyst volume and improves kidney function in the Han:SPRD (Cy/+) rat model of ADPKD. Since endothelial dysfunction and inflammatory activity are evident in patients with ADPKD, we investigated whether lovastatin reduces the inflammation and vascular dysfunction and improves kidney cell energy metabolism of Cy/+ rats.
- 29 December 2011
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 27 (7) , 2862-2865
The impact of type II diabetes mellitus in patients with autosomal dominant polycystic kidney disease
The epidemic of obesity and diabetes is increasing within the USA and worldwide. We have previously shown that body mass index has increased significantly in autosomal dominant polycystic kidney disease (ADPKD) subjects seen at our center in more recent years. However, the impact of Type II diabetes in ADPKD patients has not been well studied. This retrospective cohort study compared clinical characteristics in 44 pre-renal transplant patients with ADPKD and diabetes and 88 age- and sex-matched non-diabetic patients with ADPKD who were seen at the University of Colorado between 1977 and 2008. The primary outcomes in this study were renal volume determined by renal ultrasonography, renal function assessed by estimated glomerular filtration rate and time to onset of end-stage renal disease or death by Kaplan-Meier analyses. Diabetic patients had significantly larger kidney volumes than those with ADPKD alone [geometric mean (95% confidence interval (CI)]: 2456 (1510-3992) versus 1358 (1186-1556) cm3, P=0.02. Among those whose age at hypertension diagnosis was known, the diabetic ADPKD patients had earlier median (95% CI) age at onset of hypertension compared to those with ADPKD alone: 32.5 (28-40) versus 38 (35-42) years, P=0.04. Diabetic ADPKD patients tended to have an earlier median age of death than those with ADPKD alone. Patients with ADPKD and type II diabetes have larger renal volumes, earlier age at diagnosis of hypertension and may die at a younger age compared to those patients with ADPKD alone. This study emphasizes the importance of diabetes risk management in ADPKD.
- 29 December 2011
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 27 (7) , 2862-2865
The impact of type II diabetes mellitus in patients with autosomal dominant polycystic kidney disease
The epidemic of obesity and diabetes is increasing within the USA and worldwide. We have previously shown that body mass index has increased significantly in autosomal dominant polycystic kidney disease (ADPKD) subjects seen at our center in more recent years. However, the impact of Type II diabetes in ADPKD patients has not been well studied. This retrospective cohort study compared clinical characteristics in 44 pre-renal transplant patients with ADPKD and diabetes and 88 age- and sex-matched non-diabetic patients with ADPKD who were seen at the University of Colorado between 1977 and 2008. The primary outcomes in this study were renal volume determined by renal ultrasonography, renal function assessed by estimated glomerular filtration rate and time to onset of end-stage renal disease or death by Kaplan-Meier analyses. Diabetic patients had significantly larger kidney volumes than those with ADPKD alone [geometric mean (95% confidence interval (CI)]: 2456 (1510-3992) versus 1358 (1186-1556) cm3, P=0.02. Among those whose age at hypertension diagnosis was known, the diabetic ADPKD patients had earlier median (95% CI) age at onset of hypertension compared to those with ADPKD alone: 32.5 (28-40) versus 38 (35-42) years, P=0.04. Diabetic ADPKD patients tended to have an earlier median age of death than those with ADPKD alone. Patients with ADPKD and type II diabetes have larger renal volumes, earlier age at diagnosis of hypertension and may die at a younger age compared to those patients with ADPKD alone. This study emphasizes the importance of diabetes risk management in ADPKD.
- Open Access
- 1 January 2011
- Published by Elsevier in Kidney International
- Vol. 79 (1) , 128-134
Angiogenic growth factors correlate with disease severity in young patients with autosomal dominant polycystic kidney disease
- 1 January 2011
- Published by Elsevier in Kidney International
- Vol. 79 (1) , 128-134
Open AccessAngiogenic growth factors correlate with disease severity in young patients with autosomal dominant polycystic kidney disease